113 related articles for article (PubMed ID: 24984532)
1. Importance of platinum-free interval in second-line chemotherapy for advanced or recurrent endometrial cancer.
Matoda M; Omatsu K; Yamamoto A; Nomura H; Tanigawa T; Kawamata Y; Kato K; Umayahara K; Takeshima N
Eur J Gynaecol Oncol; 2014; 35(3):224-9. PubMed ID: 24984532
[TBL] [Abstract][Full Text] [Related]
2. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
[TBL] [Abstract][Full Text] [Related]
3. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
4. What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Nagao S; Nishio S; Okada S; Otsuki T; Fujiwara K; Tanabe H; Takano M; Hasumi Y; Takei Y; Hasegawa T; Matsumoto T; Fujiwara K; Takekuma M; Nakamura K; Shimada M; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2015 Aug; 76(2):335-42. PubMed ID: 26092322
[TBL] [Abstract][Full Text] [Related]
5. Decision-making for Subsequent Therapy for Patients With Recurrent or Advanced Endometrial Cancer Based on the Platinum-free Interval.
Yasunaga M; Yahata H; Okugawa K; Hori E; Hachisuga K; Maenohara S; Kodama K; Yagi H; Ohgami T; Onoyama I; Asanoma K; Kato K
Am J Clin Oncol; 2023 Sep; 46(9):387-391. PubMed ID: 37272748
[TBL] [Abstract][Full Text] [Related]
6. Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
Matoda M; Tanigawa T; Omatsu K; Ushioda N; Yamamoto A; Okamoto S; Kawamata Y; Kato K; Umayahara K; Takeshima N
Int J Gynecol Cancer; 2013 Nov; 23(9):1670-4. PubMed ID: 24172102
[TBL] [Abstract][Full Text] [Related]
7. The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Takekuma M; Mori K; Iida T; Kurihara K; Saitou M; Tokunaga H; Kawana K; Ikeda M; Satoh T; Saito T; Miyagi E; Nagai Y; Furusawa A; Kawano Y; Kawano K; Tabata T; Ota Y; Hayase R; Mikami M; Sugiyama T
Cancer Chemother Pharmacol; 2017 Oct; 80(4):697-705. PubMed ID: 28785994
[TBL] [Abstract][Full Text] [Related]
8. Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.
Takekuma M; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
J Gynecol Oncol; 2015 Jul; 26(3):185-92. PubMed ID: 26197856
[TBL] [Abstract][Full Text] [Related]
9. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy.
Tanioka M; Katsumata N; Yonemori K; Kouno T; Shimizu C; Tamura K; Ando M; Fujiwara Y
Cancer Chemother Pharmacol; 2011 Aug; 68(2):337-42. PubMed ID: 20976599
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer.
Ninomiya T; Yamagami W; Susumu N; Makabe T; Sakai K; Wada M; Takigawa A; Chiyoda T; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
Anticancer Res; 2016 Apr; 36(4):1751-8. PubMed ID: 27069155
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Emons G; Kurzeder C; Schmalfeldt B; Neuser P; de Gregorio N; Pfisterer J; Park-Simon TW; Mahner S; Schröder W; Lück HJ; Heubner ML; Hanker L; Thiel F; Hilpert F
Gynecol Oncol; 2016 Mar; 140(3):450-6. PubMed ID: 26731724
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis.
Mevius A; Karl F; Wacker M; Welte R; Krenzer S; Link T; Maywald U; Wilke T
J Cancer Res Clin Oncol; 2023 May; 149(5):1929-1939. PubMed ID: 35840862
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Features of Recurrent Endometrial Cancer in Japan: Chemotherapy Instead of Radiotherapy as Postoperative Adjuvant Treatment.
Iwase H; Furukawa S; Hirasawa T; Asai S; Ohara T; Hosonuma S; Endo S; Tazo Y; Sato H; Takada T; Arai M; Ikeda M; Shida M; Yoshioka N; Tozawa-Ono A; Suzuki N; Mikami M; Onda T
Int J Gynecol Cancer; 2018 Oct; 28(8):1616-1623. PubMed ID: 30095709
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
16. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
[TBL] [Abstract][Full Text] [Related]
19. Primary chemotherapy-associated effect of second-line chemotherapy on survival of patients with advanced ovarian cancer.
Isonishi S; Hirama M; Saitou M; Yasuda M; Tanaka T
Int J Clin Oncol; 2006 Jun; 11(3):236-42. PubMed ID: 16850131
[TBL] [Abstract][Full Text] [Related]
20. Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study.
Martins D; O'Sullivan DE; Boyne DJ; Cheung WY; Allonby O; Habash M; Brenner DR; Riemer J; McGee J
Curr Oncol; 2023 Feb; 30(2):2277-2289. PubMed ID: 36826137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
